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SUPPLEMENTARY NOTES
ABSTRACT
Protocadherin-PC (PCDH-PC or PCDH11Y) is a human-, male-specific gene product that is upregulated in prostate cancer cells by androgen deprivation therapy. Silencing of this gene product with PCDH-PC-specific siRNA drastically induced the death of prostate cancer cells cultured in the absence of androgens and we have proposed that PCDH-PC expression knockout by shRNAs or antisense oligonucleotides (ASOs) might be useful in preventing the development of castration-recurrent prostate cancer in prostate cancer patients. To this end, we have created functional shRNA vectors and ASOs capable of suppressing PCDH-PC expression and we have also created a monoclonal antibody that allows us to detect PCDH-PC protein in cell extracts or tissues. The antibody preferentially recognizes prostate cancer cells in human prostate specimens. Knockdown of PCDH-PC expression by the shRNA vectors is more efficient than with siRNA and is apparently sufficient to kill prostate cancer cells even under conditions where androgen is available and this further supports the idea that PCDH-PC contributes to the biological properties and survival of prostate cancer cells.
SUBJECT TERMS
None provided. Background: Protocadherin-PC (PCDH-PC) is an androgen-repressed gene encoded on the human Y-chromosome that is over-expressed in prostate cancer cells that were selected for resistance to apoptosis (1) . Transfection of this gene product back into prostate cancer cells induces apoptosisand hormone-resistance (1, 2) . PCDH-PC is also highly upregulated in androgen-sensitive human prostate cancer cells when they are exposed to androgen-free conditions (1). In our preliminary studies, we found that a small interfering (si) RNA (siRNA) that targets and suppresses the expression of PCDH-PC was able to induce prostate cancer cells under androgen-free conditions. Based upon these results, we proposed that agents that target and block PCDH-PC expression might be used in conjunction with hormonal therapy to increase response and survival of advanced (metastatic) prostate cancer patients. The work in this project will develop and test strategies to suppress PCDH-PC expression in prostate cancer cells based on shRNA and antisense oligonucleotide targeting. Other work will test whether cultured human prostate cancer cells (LNCaP) that are crippled with regards to their ability to upregulate PCDH-PC (by transfection with a PCDH-PC specific targeting shRNA), are killed when they transferred to androgen-deprived medium and whether these cells are unable to form hormone-refractory tumors when xenografted into male immunodeficient mice that are subsequently castrated. We will also test whether the treatment of LNCaP-xenografted mice with antisense oligonucleotides that target PCDH-PC, prevent these mice from developing hormone refractory tumors after they are castrated. In summary, the work in this project will pre-clinically test the idea that PCDH-PC targeting strategies might be a useful adjuvant therapeutic when advanced prostate cancer patients undergo hormonal therapy.
Body:
This project has 4 Specific Aims and progress will be discussed for each Aim.
Specific Aim 1. Design shRNA expression plasmids that suppress PCDH-PC expression in LNCaP cells and isolate transfected variants of the LNCaP cell line that are unable to induce PCDH-PC expression when cultured in androgen-free medium.
Work Done: We identified two PCDH-PC shRNA vectors (purchased from SBI, Inc., #310598 and 310600) that effectively silence PCDH-PC expression by greater than 90% in cells (293T-T6 or LNCaP-T6) that overexpress this protein ( Figure 1 ). These vectors also carry the gene encoding puromycin resistance so one can use them to create stable cell lines that express the shRNAs. However, when we attempted to stably transfect these shRNA vectors into parental LNCaP prostate cancer cells (that we believed express low levels of PCDH-PC), we were not able to obtain any puromycin-resistant clones. In contrast, transfection by either of two control (non-targeting) shRNA vectors (#30003 and #20003) resulted in abundant puromycin-resistant colonies (> 200/dish). The experiment was repeated twice with similar results. We then considered the possibility that puromycin selection was suboptimal for LNCaP cell lines so we re-cloned the shRNA sequences from 310598 and 310600 (as well as the control non-targeting shRNA sequences) into a different vector that expressed green fluorescent protein (GFP) as well as the blasticin-resistance protein from separate promoters. Here again, we were easily able to select blasticin-resistant clones when cells were transfected with the control vectors but unable to obtain blasticin-resistant clones from cells transfected with 31058 or 310600. The results suggest that the shRNAs encoded by 31058 and 310600 are generically toxic for LNCaP cells regardless of their androgenic millieu. These results were unexpected since our previous work with LNCaP cells (of high passage) showed that these cells express little, if any PCDH-PC RNA or protein when cultured in normal conditions so we did not anticipate that PCDH-PC targeting shRNA could be lethal for the cells. We then decided to test whether these two PCDH-PC targeting shRNAs were similarly lethal to prostate cancer cells through a mechanism that did not involve PCDH-PC suppression, We transfected control (non-targeting) shRNAs or 310598 and 310600 into PC-3 cells that lack the human Y-chromosome on which the human PCDH-PC gene is encoded. Both control and PCDH-PC-targeting shRNAs gave rise to numerous PC-3 blasticin-resistant colonies so these results continue to support the idea that the parental LNCaP cells that we used must be making some PCDH-PC gene product that is important for their survival.
In hindsight, we recognized that this new work was done with LNCaP cells that were only recently obtained from the ATCC (i.e. low passage cells) in contrast to the high passage variant of these cells which we had previously used for all of our experiments. We then tested, by quantitative PCR (qPCR), whether there was a difference in the amount of PCDH-PC RNA expressed in LNCaP cells as a function of relative passage number. Indeed, (Figure 2a) , qPCR quantification of PCDH-PC mRNA levels in low passage vs high passage LNCaP cells showed that the low passage cells express much higher basal levels of PCDH-PC mRNA (> 700-fold) than high passage LNCaP cells when grown under normal (in standard fetal bovine containing medium or in charcoal stripped fetal bovine serum supplemented with androgen) conditions. For our purposes, the results indicate the unexpected results that low passage LNCaP variants already express a considerable amount of PCDH-PC gene product, even in the presence of androgen, (Figure 2a ) and the fact that these cells do not survive transfection with PCDH-PC targeting shRNAs suggests that the cells may be dependent on this expression. It is of interest to note that despite the extensive difference in basal expression of PCDH-PC between low or high passaged LNCaP cells, both cell types further upregulated PCDH-PC mRNA expression to a similar extent (Figure 2b ) so our observations of an induction of this gene product in androgen free medium remain supported in either cell type. Figure 3 (below), are the results obtained when this ASO was applied to the medium of cells that were previously transfected with a PCDH-PC expression plasmid in which the PCDH-PC protein is "tagged" by a myc-peptide. Expression of the PCDH-PC protein is identified using an anti-myc antibody on Western blots. Results show that this ASO is effective in silencing PCDH-PC expression at an approximately 200 μM concentration or greater. In summary, ASO #181 suitably targets PCDH-PC at concentrations above 200 μM and essentially completes the work described for Specific Aim 2 though we also should consider alternate ASO design based upon other potential targeting sites.
Specific Aim 3. Test PCDH-PC expression reduction strategies (shRNA or ASO targeting) for ability to induce death of LNCaP cells in vitro in androgen-free medium.
Work Done: As discussed in the work under Specific Aim 1, PCDH-PC shRNAs were lethal for low passage LNCaP cells that express high amounts of PCDH-PC, even when these cells were grown in androgen-supplemented medium. During the extension year, we will test this in high passage LNCaP cells that can be induced to express PCDH-PC to high levels when they are deprived of androgen. Additionally, during the last year, we developed an efficient tetracycline-inducible PCDH-PC expression vector (Figure 4 , next page) that will enable us to test: 1) whether upregulation of this expression vector confers androgen independent growth in prostate cancer lines other than LNCaP and whether, by blocking its upregulation, we can suppress the acquisition of androgen independent growth. Specific Aim 4 Proof-of-principle and pre-clinical testing of targeted PCDH-PC expression knockout combined with androgen deprivation as a strategy for prostate cancer therapy using mouse xenograft tumor models.
No work was done on this Specific Aim during the last period. Although the PI had an approved protocol to conduct this work in the nearby UAlbany Animal Facilities (that extends to Feb 16 2010), the cost of the work for unaffiliated investigators was prohibitive and far outside the budget provided. The Ordway Research Institute (ORI) has now opened its own Animal Facility and the PI has submitted a protocol for this work that is now under review by the ORI IACUC. This work will be undertaken in the continuation year.
Additional work was also undertaken outside of the original Specific Aims. Though not specified in the original Specific Aims, we feel that this work is relevant to the outcome of this project. Figure 5A shows the relative expression (qPCR data indexed to GAPDH expression in the same specimen) of these two genes as a function of time after androgen withdrawal (CS-FBS). The kinetics of their induction is extremely similar. To further test for a potential relationship between these two gene products, we transfected LNCaP cells with a PCDH-PC expression vector and then compared expression of SHH 48 hrs later to cells that were transfected with a control (empty) vector. As is shown in Figure 4B , SHH expression is increased over 50-fold in the cells that were transfected with PCDH-PC. We are currently testing whether si/shRNA that targets PCDH-PC prevents the upregulation of SHH in androgen deprived medium. 
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